Pancreatic cancer is one of the killers of serious public health threats. The data show that about 55,000 people will be diagnosed with this disease in the United States this year, and more than 44,000 people will die. Currently, the five-year survival rate of pancreatic cancer is only 7%, and the drugs for treating this invasive disease are limited. However, according to the latest research progress, a new drug called Meavert can effectively prevent tumor growth and spread in mice, and can prevent drug resistance during chemotherapy.
The latest results were published in Gastroenterology by researchers at the Samuel Oschin Comprehensive Cancer Institute from Cedars-Sinai under the title "An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice."
95% of patients with pancreatic cancer are diagnosed with pancreatic ductal adenocarcinoma (PDAC), which is developed by cells in the pancreatic duct. Because cancer cells cause normal cells called stellate cells in the pancreas to produce pancreatic scar tissue, and scar tissue makes it difficult for chemotherapy drugs and blood to enter the pancreas, PDAC is difficult to treat.
On the other hand, the interaction of cancer and stellate cells also creates an enabling environment that stimulates the growth and spread of local tumors. In addition, the increased levels of activity of certain enzymes also increase resistance to cancer treatment.
In this new study, the authors summarize several major features of the new drug Metavert:
(1) Metavert significantly reduced the survival rate of PDAC cells (rather than the survival rate of untransformed cells);
(2) Decreased epithelial mesenchymal transition (EMT, a biological process in which epithelial cells are transformed into a mesenchymal phenotype cell by a specific procedure) and stem cells in a PDAC cell line;
(3) The survival rate of cancer cells cultured with Metavert in combination with paclitaxel or gemcitabine is reduced compared to cells cultured with either drug alone;
(4) Metavert increased the killing of drug-resistant PDAC cells by paclitaxel and gemcitabine;
(5) Normal glucose metabolism was obtained from PDAC cells cultured in Metavert;
(6) Administration of Metavert (alone or in combination with gemcitabine) to KPC mice or mice with isogenic tumors significantly increased their survival, slowed tumor growth, prevented tumor metastasis, and reduced tumor-related Tumor infiltration of macrophages reduces blood cytokine levels.
In four years, researchers have designed and synthesized new chemicals that inhibit the activity of cancer cells. They found that Metavert blocked drug resistance and significantly enhanced the positive effects of radiation therapy and two chemotherapy drugs commonly used in humans. In a mouse study, Metavert increased survival by approximately 50%.
Dr. Mouad Edderkaoui, assistant professor of medicine and biomedical science at Cedars-Sinai, explained: "This is an exciting step to improve the survival rate of patients with pancreatic cancer. If the results are confirmed in humans, we may develop a drug. Significantly prolongs the lifespan of patients with fatal disease in PDAC."
Currently, the Cedars-Sinai team is developing a drug for human testing.
Souce: NovoPro 2018-09-27